Johnson & Johnson Income from Discontinued Operations 2010-2024 | JNJ
Johnson & Johnson annual/quarterly income from discontinued operations history and growth rate from 2010 to 2024. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
- Johnson & Johnson income from discontinued operations for the quarter ending June 30, 2024 was $M, a 100% decline year-over-year.
- Johnson & Johnson income from discontinued operations for the twelve months ending June 30, 2024 was $21.636B, a 1127.92% increase year-over-year.
- Johnson & Johnson annual income from discontinued operations for 2023 was $21.827B, a 1289.37% increase from 2022.
- Johnson & Johnson annual income from discontinued operations for 2022 was $1.571B, a 48.94% decline from 2021.
- Johnson & Johnson annual income from discontinued operations for 2021 was $3.077B, a INF% increase from 2020.
Johnson & Johnson Annual Income from Discontinued Operations
(Millions of US $) |
| 2023 |
$21,827 |
| 2022 |
$1,571 |
| 2021 |
$3,077 |
| 2020 |
$ |
| 2019 |
$ |
| 2018 |
$ |
| 2017 |
$ |
| 2016 |
$ |
| 2015 |
$ |
| 2014 |
$ |
| 2013 |
$ |
| 2012 |
$ |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
Johnson & Johnson Quarterly Income from Discontinued Operations
(Millions of US $) |
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
$-83 |
| 2023-09-30 |
$21,719 |
| 2023-06-30 |
$-232 |
| 2023-03-31 |
$423 |
| 2022-12-31 |
$1,423 |
| 2022-09-30 |
$148 |
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
|
| 2016-09-30 |
|
| 2016-06-30 |
|
| 2016-03-31 |
|
| 2015-12-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$384.413B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
